Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants

Clinical Microbiology Reviews

Volumn 16, Issue 4, 2003, Pages 647-657

  Meijer, Ellen ^a   Boland, Greet J ^b   Verdonck, Leo F ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; CIDOFOVIR; FOSCARNET; GANCICLOVIR; HLA ANTIGEN CLASS 1; VALACICLOVIR; VALGANCICLOVIR; VIRUS DNA;

ADOPTIVE IMMUNOTHERAPY; ALLOGRAFT; CELL TRANSPLANTATION; CLINICAL TRIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; EYE TOXICITY; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HUMAN; INFECTION RISK; LYMPHOCYTE COUNT; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; NONHUMAN; POLYMERASE CHAIN REACTION; RASH; RECIPIENT; REVIEW; SENSITIVITY ANALYSIS; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; VIRUS DETECTION; VIRUS REACTIVATION; VOMITING;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS; DNA VIRUSES;

EID: 0142095001     PISSN: 08938512     EISSN: None     Source Type: Journal    
DOI: 10.1128/CMR.16.4.647-657.2003     Document Type: Review

References (102)

1. Aono, T., K. Kondo, H. Miyoshi, K. Tanaka-Taya, M. Kondo, Y. Osugi, J. Hara, S. Okada, and K. Yamanishi. 1998. Monitoring of human cytomegalovirus infections in pediatric bone marrow transplant recipients by nucleic acid sequence-based amplification. J. Infect. Dis. 178:1244-1249.
2. Aubert, G., A. F. Hassan-Walker, J. A. Madrigal, V. C. Emery, C. Morte, S. Grace, M. B. C. Koh, M. Potter, H. G. Prentice, A. Dodi, and P. J. Travers. 2001. Cytomegalovirus-specific cellular immune responses and viremia in recipients of allogeneic stem cell transplants. J. Infect. Dis. 184:955-963.
3. Bacigalupo, A., E. Tedone, M. T. Van Lint, G. Trespi, M. Lonngren, M. A. Sanna, F. Moro, F. Frassoni, D. Occhini, F. Gualandi, T. Lamparelli, G. Hale, and A. M. Marmont. 1994. CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections. Bone Marrow Transplant. 13:783-788.
4. Bacigalupo, A., M. T. Van Lint, E. Tedone, F. Moro, M. A. Sanna, M. Lonngren, G. Trespi, F. Frassoni, D. Occhini, F. Gualandi, T. Lamparelli, and A. M. Marmont. 1994. Early treatment of CMV infections in allogeneic bone marrow transplant recipients with foscarnet or ganciclovir. Bone Marrow Transplant. 13:753-758.
5. Boeckh, M., T. A. Gooley, D. Myerson, T. Cunningham, G. Schoch, and R. A. Bowden. 1996. Cytomegalovirus pp65 Ag-guided early treatment with ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 88:4063-4071.
6. Boeckh, M., G. M. Gallez-Hawkins, D. Myerson, J. A. Zaia, and R. A. Bowden. 1997. Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation. Transplantation 64:108-113.
7. Boeckh, M., and G. Boivan. 1998. Quantitation of cytomegalovirus: methodologic aspects and clinical applications. Clin. Microbiol. Rev. 11:533-554.
8. Boeckh, M., R. A. Bowden, T. A. Gooley, D. Myerson, and L. Corey. 1999. Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients. Blood 93:1781-1782.
9. Boivin, G., R. Belanger, R. Delage, C. Beliveau, C. Demers, N. Goyette, and J. Roy. 2002. Quantitative analysis of cytomegalovirus (CMV) viremia using the pp65 antigenemia assay and the Cobas Amplicor CMV monitor test after blood and marrow allogeneic transplantation. J. Clin. Microbiol. 38:4356-4360.
10. Boriskin, Y. S., K. Fuller, R. L. Powles, I. B. Vipond, P. S. Rice, J. C. Booth, E. O. Caul, and P. D. Butcher. 2002. Early detection of cytomegalovirus (CMV) infection in bone marrow transplant patients by reverse transcription-PCR for CMV spliced late gene UL21.5: a two site evaluation. J. Clin. Virol. 24:13-23.
11. Bowden, R. A., S. J. Slichter, M. H. Sayers, M. Mori, M. J. Cays, and J. D. Meyers. 1991. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood 78:246-250.
12. Bregante, S., S. Bertilson, E. Tedone, M. T. Van Lint, G. Trespi, N. Mordini, G. Berisso, F. Gualandi, T. Lamparelli, O. Figari, F. Benvenuto, A. M. Raiola, and A. Bacigalupo. 2000. Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): a dose-finding study. Bone Marrow Transplant. 26:23-29.
13. Castro-Malaspina, H., R. E. Harris, J. Gajewski, N. Ramsay, R. Collins, B. Dharan, R. King, and H. J. Deeg. 2002. Unrelated marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the national marrow donor program. Blood 99:1943-1951.
14. Chakrabarti, S., K. E. Collingham, H. Osman, C. C. Fegan, and D. W. Milligan. 2001. Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections. Bone Marrow Transplant. 28:879-881.
15. Craddock, C., R. M. Szydlo, F. Dazzi, E. Olavarria, K. Cwynarski, A. Yong, P. Brookes, J. de la Fuente, E. Kanfer, J. Apperley, and J. M. Goldman. 2001. Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis. Br. J. Haematol. 112:228-236.
16. Cwynarski, K., J. Ainsworth, M. Cobbold, S. Wagner, P. Mahendra, J. Ap. perley, J. Goldman, C. Craddock, and P. A. H. Moss. 2001. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood 97:1232-1240.
17. de Gast, G. C., G. J. Boland, A. M. Vlieger, R. A. de Weger, L. F. Verdonck, F. E. Zwann, and N. M. Jiwa. 1992. Abortive human cytomegalovirus infection in patients after allogeneic bone marrow transplantation. Bone Marrow Transplant. 9:221-225.
18. Eckle, T., L. Prix, G. Jahn, T. Klingebiel, R. Handgretinger, B. Selle, and K. Hamprecht. 2000. Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. Blood 96:3286-3289.
19. Einsele, H., G. Ehninger, H. Hebart, K. M. Wittkowski, U. Schuler, G. Jahn, P. Mackes, M. Herter, T. Klingebiel, J. Loffler, S. Wagner, and C. A. Muller. 1995. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 86:2815-2820.
20. Einsele, H., H. Hebart, C. Kauffman-Schneider, C. Sinzger, G. Jahn, P. Bader, T. Klingebiel, K. Dietz, J. Loffler, C. Bokemeyer, C. A. Muller, and L. Kanz. 2000. Risk factors for treatment failures in patients receiving PCR-based pre-emptive therapy for CMV infection. Bone Marrow Transplant. 25:757-763.
21. Einsele, H., E. Roosnek, N. Rufer, C. Sinzger, S. Riegler, J. Loffler, U. Grigoleit, A. Moris, H. G. Rammensee, L. Kanz, A. Kleihauer, F. Frank, G. Jahn, and H. Hebart. 2002. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 99:3916-3922.
22. Emanuel, D., I. Cunningham, K. Jules-Elysee, J. A. Brochstein, N. Kernan, J. Laver, D. Stover, D. A. White, A. Fels, B. Polsky, H. Castro-Malaspina, J. R. Peppard, P. Bartus, U. Hammerling, and R. J. O'Reilly. 1988. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann. Intern. Med. 109:777-782.
23. Emery, V. C., and P. D. Griffiths. 2000. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc. Natl. Acad. Sci. USA 97:8039-8044.
24. Erice, A., N. Borrell, W. Li, W. J. Miller, and H. H. Balfour, Jr. 1998. Ganciclovir susceptibilities and analysis of UL97 region in cytomegalovirus (CMV) isolates from bone marrow recipients with CMV disease after antiviral prophylaxis. J. Infect. Dis. 178:531-534.
25. Erice, A. 1999. Resistance of human cytomegalovirus to antiviral drugs. Clin. Microbiol. Rev. 12:286-297.
26. Flexman, J., I. Kay, R. Fonte, R. Herrmann, E. Gabbay, and S. Palladino. 2001. Differences between the quantitative antigenemia assay and the Cobas Amplicor monitor quantitative PCR assay for detecting CMV viremia in bone marrow and solid organ recipients. J. Med. Virol. 64:275-282.
27. Gerna, G., M. Furione, F. Baldanti, E. Percivalle, P. Comoli, and F. Locatelli. 1995. Quantitation of human cytomegalovirus DNA in bone marrow transplant recipients. Br. J. Haematol. 91:674-683.
28. Gerna, G., F. Baldanti, J. M. Middeldorp, M. Furione, M. Zavattoni, D. Lilleri, and M. G. Revello. 1999. Clinical significance of expression of human cytomegalovirus pp67 late transcript in heart, lung, and bone marrow transplant recipients as determined by nucleic acid sequence-based amplification. J. Clin. Microbiol. 37:902-911.
29. Gerna, G., F. Baldanti, D. Lilleri, M. Parea, E. Alessandrino, A. Pagani, F. Locatelli, J. M. Middeldorp, and M. G. Revello. 2000. Human cytomegalovirus immediate-early mRNA detection by nucleic acid sequence-based amplification as a new parameter for preemptive therapy in bone marrow transplant recipients. J. Clin. Microbiol. 38:1845-1853.
30. Gilbert, C., J. Roy, R. Belanger, R. Delage, C. Beliveau, C. Demers, and G. Boivin. 2001. Lack of emergence of cytomegalovirus UL97 mutations conferring ganciclovir (GCV) resistance following preemptive GCV therapy in allogeneic stem cell transplant recipients. Antimicrob. Agents Chemother. 45:3669-3671.
31. Goodrich, J. M., R. A. Bowden, L. Fisher, C. Keller, G. Schoch, and J. D. Meyers. 1993. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann. Intern. Med. 118:173-178.
32. Gratama, J. W., J. W. J. van Esser, C. H. J. Lamers, C. Tournay, B. Lowenberg, R. L. H. Bolhuis, and J. J. Cornelissen. 2001. Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood 98:1358-1364.
33. Griscelli, F., M. Barrois, S. Chauvin, S. Lastere, D. Bellet, and J. H. Bourhis. 2001. Quantification of human cytomegalovirus DNA in bone marrow transplant recipients by real-time PCR. J. Clin. Microbiol. 39:4362-4369.
34. Hamprecht, K., T. Eckle, L. Prix, C. Faul, H. Einsele, and G. Jahn. 2003. Ganciclovir-resistant cytomegalovirus disease after allogeneic stem cell transplantation: pitfalls of phenotypic diagnosis by in vitro selection of an UL97 mutant strain. J. Infect. Dis. 187:139-143.
35. Hebart, H., C. Muller, J. Loffler, G. Jahn, and H. Einsele. 1996. Monitoring of CMV infection: a comparison of PCR from whole blood, plasma-PCR, pp65-antigenemia and virus culture in patients after bone marrow transplantation, Bone Marrow Transplant. 17:861-868.
36. Hebart, H., D. Gamer, J. Loeffler, C. Mueller, C. Sinzger, G. Jahn, P. Bader, T. Klingebiel, L. Kanz, and H. Einsele. 1998. Evaluation of Murex CMV DNA hybrid capture assay for detection and quantitation of cytomegalovirus infection in patients following allogeneic stem cell transplantation. J. Clin. Microbiol. 36:1333-1337.
37. Reference deleted.
38. Hebart, H., S. Daginik, S. Stevanovic, U. Grigoleit, A. Dobler, M. Baur, G. Rauser, C. Sinzger, G. Jahn, J. Loeffler, L. Kanz, H. G. Rammensee, and H. Einsele. 2002. Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-gamma-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation. Blood 99:3830-3837.
39. Hebart, H., T. Rudolph, J. Loeffler, J. Middeldorp, T. Ljubicic, G. Jahn, and H. Einsele. 2002. Evaluation of the NucliSens CMV pp67 assay for detection and monitoring of human cytomegalovirus infection after allogeneic stem cell transplantation. Bone Marrow Transplant. 30:181-187.
40. Hiyoshi, M., S. Tagawa, T. Takubo, K. Tanaka, T. Nakao, Y. Higeno, K. Tamura, M. Shimaoka, A. Fujii, M. Higashihata, Y. Yasui, T. Kim, A. Hiraoka, and N. Tatsumi. 1997. Evaluation of the Amplicor CMV test for direct detection of cytomegalovirus in plasma specimens. J. Clin. Microbiol. 10:2692-2694.
41. Humar, A., S. Wood, J. Lipton, H. Messner, J. Meharchand, A. McGeer, K. MacDonald, and T. Mazzulli. 1998. Effect of cytomegalovirus infection on 1-year mortality rates among recipients of allogeneic bone marrow transplants. Clin. Infect. Dis. 26:606-610.
42. Humar, A., J. Lipton, S. Welsh, G. Moussa, H. Messner, and T. Mazzulli. 2001. A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients. Bone Marrow Transplant. 28:485-490.
43. Reference deleted.
44. Kanda, Y., S. Chiba, T. Suzuki, M. Kami, Y. Yazaki, and H. Hirai. 1998. Time course analysis of semi-quantitative PCR and antigenemia assay for prevention of cytomegalovirus disease after bone marrow transplantation. Br. J. Haematol. 100:222-225.
45. Kanda, Y., S. Mineishi, T. Saito, S. Seo, A. Saito, M. Ohnishi, K. Suenaga, H. Niiya, K. Nakai, T. Takeuchi, and Y. Takaue. 2001. Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single center experience in Japan. Bone Marrow Transplant. 27:437-444.
46. Keenan, R. D., J. Ainsworth, N. Khan, R. Bruton, M. Cobbold, M. Assenmacher, D. W. Milligan, and P. A. Moss. 2001. Purification of cytomegalovirus-specific CD8 T cells from peripheral blood using HLA-peptide tetramers. Br. J. Haematol. 115:428-434.
47. Reference deleted.
48. Krause, H., H. Hebart, G. Jahn, C. A. Muller, and H. Einsele. 1997. Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease. Bone Marrow Transplant. 19:1111-1116.
49. Kröger, N., T. Zabelina, W. Krüger, H. Renges, N. Stute, J. Schrum, H. Kabisch, P. Schafhausen, N. Jaburg, C. Loliger, P. Schafer, A. Hinke, and A. R. Zander. 2001. Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with antithymocyte globulin. Br. J. Haematol. 113:1060-1071.
50. Li, C. R., P. D. Greenberg, M. J. Gilbert, J. M. Goodrich, and S. R. Riddell. 1994. Recovery of HLA-restricted cytomegalovirus (CVM)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 83:1971-1979.
51. Lim, J. B., M. Provenzano, M. Bettinotti, and D. F. Stroncek. 2001. Identification of a new candidate HLA-A3 restricted CMV epitope as a target antigen to induce specific CMV cytotoxic lymphocytes. Blood 98:S780a. (Abstract 3244.)
52. Ljungman, P., K. Lore, J. Aschan, S. Klaesson, I. Lewensohn-Fuchs, B. Lonnqvist, O. Ringden, J. Winiarski, and A. Ehrnst. 1996. Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant recipients. Bone Marrow Transplant. 17:583-587.
53. Ljungman, P., G. Oberg, J. Aschan, A. Ehrnst, B. Lonnqvist, K. Pauksen, and P. Sulila. 1996. Foscarnet for pre-emptive therapy of CMV infection detected by a leukocyte-based nested PCR in allogeneic bone marrow transplant patients. Bone Marrow Transplant. 18:565-568.
54. Ljungman, P. 2001. Prophylaxis against herpesvirus infections in transplant recipients. Drugs 61:187-196.
55. Ljungman, P., G. Lambertenghi Deliliers, U. Platzbecker, S. Matthes-Martin, A. Bacigalupo, H. Einsele, J. Ullman, M. Musso, R. Trenschel, P. Ribaud, M. Bornhauser, and C. Cordonnier. 2001. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. Blood 97:388-392.
56. Ljungman, P., R. de la Camara, N. Milpied, L. Volin, C. A. Russell, A. Crisp, and A. Webster. 2002. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood 99:3050-3056.
57. Longmate, J., J. York, C. La Rosa, R. Krishan, M. Zhang, D. Senitzer, and D. J. Diamond. 2001. Population coverage by HLA class-I restricted cytotoxic T-lymphocyte epitopes. Immunogenetics 52:165-173.
58. Machado, C. M., F. L Dulley, L. S. Vilas Boas, J. B. Castelli, M. C. A. Macedo, R. L. Silva, R. Pallota, R. S. Saboya, and C. S. Pannuti. 2000. CMV pneumonia in allogeneic recipients undergoing early treatment or pre-emptive ganciclovir therapy. Bone Marrow Transplant. 26:413-417.
59. Machado, C. M., R. X. Menezes, M. C. A. Macedo, A. V. A. Mendes, L. S. Vilas Boas, J. B. Castelli, F. L. Dulley, and C. S. Pannuti. 2001. Extended antigenemia surveillance and late cytomegalovirus infection after allogeneic BMT. Bone Marrow Transplant. 28:1053-1059.
60. Machida, U., M. Kami, T. Fukui, Y. Kazuyama, M. Kinoshita, Y. Tanaka, Y. Kanda, S. Ogawa, H. Honda, and H. Hirai. 2000. Real-time automated PCR for early diagnosis and monitoring of cytomegalovirus infection after bone marrow transplantation. J. Clin. Microbiol. 38:2536-2542.
61. Manteiga, R., R. Martino, A. Sureda, R. Labeaga, S. Brunet, J. Sierra, and N. Rabella. 1998. Cytomegalovirus pp65 antigenemia-guided pre-emptive treatment with ganciclovir after allogeneic stem cell transplantation: a single-center experience. Bone Marrow Transplant. 22:899-904.
62. Matsunaga, T., S. Sakamaki, S. Ishigaki, K. Kohda, M. Takeda, J. Katoh, H. Kuroda, Y. Hirayama, T. Kusakabe, T. Akiyama, T. Kuga, Y. Niitsu, T. Masaoka, T. Sagawa, and Y. Matsumoto. 1999. Use of PCR serum in diagnosing and monitoring cytomegalovirus reactivation in bone marrow transplant recipients. Int. J. Hematol. 69:105-111.
63. Meijer, E., A. W. Dekker, M. Rozenberg-Arska, A. J. L. Weersink, and L. F. Verdonck. 2002. Influence of cytomegalovirus-seropositivity on outcome after T cell depleted bone marrow transplantation: contrasting results between recipients of grafts from related and unrelated donors. Clin. Infect. Dis. 35:703-712.
64. Meyers, J. D., N. Flournoy, and E. D. Thomas. 1986. Risk factors for cytomegalovirus infection after human marrow transplantation. J. Infect. Dis. 153:478-488.
65. Meyers, J. D., E. C. Reed, D. H. Shepp, M. Thornquist, P. S. Dandliker, C. A. Vicary, N. Flournoy, L. E. Kirk, J. H. Kersey, D. E. Thomas, and H. H. Balfour. 1988. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N. Engl. J. Med. 318:70-75.
66. Moretti, S., P. Zikos, M. T. Van Lint, E. Tedone, D. Occhini, F. Gualandi, T. Lamparelli, N. Mordini, G. Berisso, S. Bregante, B. Bruno, and A. Bacigalupo. 1998. Foscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study. Bone Marrow Transplant. 22:175-180.
67. Mori, T., S. Okamoto, S. Matsuoka, T. Yajima, M. Wakui, R. Watanabe, A. Ishida, Y. Iwao, M. Mukai, T. Hibi, and Y. Ikeda. 2000. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant. 25:765-769.
68. Mori, T., S. Okamoto, R. Watanabe, T. Yajima, Y. Iwao, R. Yamazaki, T. Nakazato, N. Sato, T. Iguchi, H. Nagayama, N. Takayama, T. Hibi, and Y. Ikeda. 2002. Dose-adjusted pre-emptive therapy for cytomegalovirus disease based on real-time polymerase chain reaction after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 29:777-782.
69. Nichols, W. G., and M. Boeckh. 2000. Recent advances in the therapy and prevention of CMV infections. J. Clin. Virol. 16:25-40.
70. Nichols, W. G., L. Corey, T. Gooley, C. Davis, and M. Boeckh. 2002. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J. Infect. Dis. 185:273-282.
71. Ordemann, R., R. Naumann, G. Geissler, F. Kroschinsky, M. Bornhauser, R. Schwerdtfeger, and G. Ehninger. 2000. Foscarnet-an alternative for cytomegalovirus prophylaxis after allogeneic stem cell transplantation. Ann. Hematol. 79:432-436.
72. Ozdemir, E., L. S. St. John, G. Gillespie, S. Rowland-Jones, R. E. Champlin, J. J. Molldrem, and K. V. Komanduri. 2001. Cytomegalovirus-specific CD8+ T cell recovery, as measured by HLA-peptide tetramer staining, is insufficient to control viremia following allogeneic stem cell transplantation. Blood 98:S389a. (Abstract 1638.)
73. Peggs. K. S., W. Preiser, P. D. Kottaridis, N. McKeag, N. S. Brink, R. S. Tedder, A. H. Goldstone, D. C. Linch, and S. Mackinnon. 2000. Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation. Br. J. Haematol. 111:782-790.
74. Peggs, K., S. Verfuerth, A. Pizzey, N. Khan, P. Moss, and S. Mackinnon. 2001. Cytomegalovirus-specific adoptive cellular therapy results in massive and persistent expansions of CMV-specific T-cells and significantly reduces the incidence of CMV reactivation following allogeneic transplantation. Blood 98:S779a. (Abstract 3240.)
75. Platzbecker, U., D. Bandt, C. Thiede, A. Helwig, J. Freiberg-Richter, U. Schuler, R. Plettig, G. Geissler, A. Rethwilm, G. Ehninger, and M. Bornhauser. 2001. Successful pre-emptive cidofovir treatment for CMV antigenemia after dose-reduced conditioning and allogeneic blood stem cell transplantation. Transplantation 71:880-885.
76. Preiser, W., S. Brauninger, R. Schwerdtfeger, U. Ayliffe, J. A. Garson, N. S. Brink, S. Franck, H. W. Doerr, and H. F. Rabenau. 2001. Evaluation of diagnostic methods for the detection of cytomegalovirus in recipients of allogeneic stem cell transplants. J. Clin. Virol. 20:59-70.
77. Prentice, H. G., E. Gluckman, R. L. Powles, P. Ljungman, N. J. Milpied, R. Camara, F. Mandelli, P. Kho, L. Kennedy, and A. R. Bell. 1997. Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection. Bone Marrow Transplant. 19:129-133.
78. Prix, L., K. Hamprecht, B. Holzhuter, R. Handgretinger, T. Klingebiel, and J. Jahn. 1999. Comprehensive restriction analysis of the UL97 region allows early detection of ganciclovir-resistant human cytomegalovirus in an immunocompromised child. J. Infect. Dis. 180:491-495.
79. Quinnan, G. V., N. Kirmani, A. H. Rook, J. F. Manischewitz, L. Jackson, G. Moreschi, G. W. Santos, R. Saral, and W. H. Burns. 1982. Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone marrow transplant recipients. N. Engl. J. Med. 307:7-13.
80. Reddy, V., Y. Hao, J. Lipton, J. Meharchand, M. Minden, T. Mazzulli, C. Chan, and H. A. Messner. 1999. Management of allogeneic bone marrow transplant recipients at risk for cytomegalovirus disease using a surveillance bronchoscopy and prolonged pre-emptive ganciclovir therapy. J. Clin. Virol. 13:149-159.
81. Reed, E. C., R. A. Bowden, P. S. Dandliker, K. E. Lilleby, and J. D. Meyers. 1988. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants, Ann. Intern. Med. 109:783-788.
82. Reusser, P., S. Riddell, J. D. Meyers, and P. D. Greenberg. 1991. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 78:1373-1380.
83. Reusser, P., J. G. Gambertoglio, K. Lilleby, and J. D. Meyers. 1992. Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients. J. Infect. Dis. 166:473-479.
84. Reusser, P., C. Cordonnier, H. Einsele, D. Engelhard, H. Link, A. Locasciulli, and P. Ljungman. 1996. European survey of herpesvirus resistance to antiviral drugs in bone marrow transplant recipients. Bone Marrow Transplant. 17:813-817.
85. Reusser, P. 2001. Oral valganciclovir: a new option for treatment of cytomegalovirus infection and disease in immunocompromised hosts. Expert Opin. Investig. Drugs 10:1745-1753. (Erratum, 11:733, 2002.)
86. Reusser, P., H. Einsele, J. Lee, L. Volin, M. Rovira, D. Engelhard, J. Finke, C. Cordonnier, H. Link, and P. Ljungman. 2002. Randomized multicenter trial of foscarnet versus ganciclovir for pre-emptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 99:1159-1164.
87. Riddell, S. T., K. S. Watanabe, J. M. Goodrich, C. R. Li, M. E. Agha, and P. D. Greenberg. 1992. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257:238-241.
88. Schmidt, G. M., D. A. Horak, J. C. Niland, S. R. Duncan, S. J. Forman, and J. A. Zaia. 1991. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. N. Engl. J. Med. 324:1005-1011.
89. Schulenburg, A., T. Watkins-Riedel, H. T. Greinix, W. Rabitsch, H. Loidolt, F. Keil, M. Mitterbauer, and P. Kalhs. 2001. CMV monitoring after peripheral blood stem cell and bone marrow transplantation by pp65 antigen and quantitative PCR. Bone Marrow Transplant. 28:765-768.
90. Seropian, S., D. Ferguson, E. Salloum, D. Cooper, and M. L. Landry. 1998. Lack of reactivity to CMV pp65 antigenemia testing in a patient with CMV disease following allogeneic bone marrow transplant. Bone Marrow Transplant. 22:507-509.
91. Slavin, M. A., R. R. Bindra, C. A. Gleaves, M. B. Pettinger, and R. A. Bowden. 1993. Ganciclovir sensitivity of cytomegalovirus at diagnosis and during treatment of cytomegalovirus pneumonia in marrow transplant recipients. Antimicrob. Agents Chemother. 37:1360-1363.
92. Small, T. N., E. P. Papadopoulos, F. Boulad, T. Kiehn, J. Stiles, K. Sepkowitz, and R. J. O'Reilly. 2001. Outcome of pre-emptive or prophylactic anti-viral therapy to prevent CMV disease following T cell depleted related or unrelated BMT. Blood 98:S394a. (Abstract 1659.)
93. Solano, C., I. Munoz, A. Gutierrez, A. Farga, F. Prosper, J. Garcia-Conde, D. Navarro, and C. Gimeno. 2001. Qualitative plasma PCR assay (Amplicor CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation. J. Clin. Microbiol. 39:3938-3941.
94. Reference deleted.
95. van Prooyen, H. C., J. J. Visser, W. R. van Oostendorp, G. C. de Gast, and L. F. Verdonck. 1994. Prevention of primary transfusion-associated cytomegalovirus infection in bone marrow transplant recipients by the removal of white cells from blood components with high-affinity filters. Br. J. Haematol. 87:144-147.
96. Verdonck, L. F., Y. C. E. de Graan-Hentzen, A. W. Dekker, G. C. Mudde, and G. C. de Gast. 1987. Cytomegalovirus seronegative platelets and leukocyte-poor red blood cells from random donors can prevent primary cytomegalovirus infection after bone marrow transplantation. Bone Marrow Transplant. 2:73-78.
97. Verdonck, L. F., A. W. Dekker, M. Rozenberg-Arska, and M. R. van den Hoek. 1997. A risk adapted approach with a short course of ganciclovir to prevent cytomegalovirus (CMV) pneumonia in CMV-seropositive recipients of allogeneic bone marrow transplantation. Clin. Infect. Dis. 24:901-907.
98. Vusirikala, M., S. N. Wolff, R. S. Stein, S. J. Brandt, D. S. Morgan, J. P. Greer, F. G. Schuening, J. S. Dummer, and S. A. Goodman. 2001. Valacyclovir for the prevention of cytomegalovirus infection after allogeneic stem cell transplantation: a single institution retrospective cohort analysis. Bone Marrow Transplant. 28:265-270.
99. Walter, E. A., P. D. Greenberg, M. J. Gilbert, R. J. Finch, K. S. Watanabe, E. D. Thomas, and S. R. Riddell. 1995. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333:1038-1044.
100. Winston, D. J., W. G. Ho, K. Bartoni, C. Du Mond, D. F. Ebeling, W. C. Buhles, and R. E. Champlin. 1993. Ganciclovir prophylaxis of cytomegalovirus infection in allogeneic bone marrow transplant recipients. Ann. Intern. Med. 118:179-184.
101. Wolf, D. G., I. Yaniv, A. Honigman, I. Kassis, T. Schonfeld, and S. Ashkenazi. 1998. Early emergence of ganciclovir-resistant human cytomegalovirus strains in children with primary combined immunodeficiency. J. Infect. Dis. 178:535-538.
102. Yakushiji, K., H. Gondo, K. Kamezaki, K. Shigematsu, S. Hayashi, M. Kuroiwa, S. Taniguchi, Y. Ohno, K. Takase, A. Numata, K. Aoki, K. Kato, K. Nagafuji, and M. Harada. 2002. Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction. Bone Marrow Transplant. 29:599-606.